AMCP Signs Letter Urging Funds for COVID Vaccine Administration; FDA Recommends EUA for Pfizer-BioNTech COVID-19 Vaccine; CDC Interim Recommendations for Allocating Initial COVID-19 Vaccine; SCOTUS Ruling on Rutledge v. PCMA; AMCP Summary of Medicare Part B MFN Model; AMCP Summary of Medicare Part D Rebate Rule; AMCP Comments on CMS Draft Guidance for CY 2022 Medicare Advantage Capitation Rates, Part C and Part D Payment Policies; Electoral College Formally Designates Joe Biden President-Elect.
Supreme Court Hears Oral Arguments in California v. Texas; AMCP Submits Comments on CMS Third COVID Interim Final Rule; AMCP Submits Comments on Medicare Coverage of Innovative Technology Proposed Rule; Pharmaceutical Supply and Payment Chain Coalition Releases Principles for Safe Access to COVID-19 Vaccine; HHS Partners with Pharmacies to Distribute COVID-19 Vaccine; CMS Releases Fourth COVID-19 Interim Final Rule with Comment Period (IFC-4); Trump Administration Releases Insurance Transparency Final Rule; FDA Releases Essential Medicines under ‘Buy American’ Executive Order; Election 2020: A Biden/Harris White House, Slim Democrat House Majority, and Senate Runoff.
AMCP Submits Comments to CMS About the Part D Medication Therapy Management Program; U.S. Supreme Court Hears Arguments in the Rutledge v. Pharmaceutical Care Management Association (PCMA) Case; President Trump’s Plan to Deliver $200 Prescription Drug Discount Cards to Seniors is Delayed; FDA Releases Guidance Regarding COVID-19 Vaccines; FDA Authorizes a Point-of-care Coronavirus Antibody Test; Senate Committee Holds Hearing on Federal Response to COVID-19.
AMCP Virtual Legislative Days 2020; AMCP Sends Letter to HHS Secretary Azar on Anti-Kickback Rules Concerns; HHS Authorizes Pharmacists to Administer COVID-19 Vaccine; AMCP Submits Comments on COVID-19 Vaccine Allocation Framework; CMS Issues Proposed Rule Establishing a New Coverage Pathway for Breakthrough Devices; CMS Issues Rule Limiting Pharmacist-Administered COVID-19 Testing; President Trump Signs Drug Pricing Executive Order.
CMS Issues Request for Information on Electronic Prescribing of Controlled Substances; President Trump Signed Executive Orders on Drug Pricing; AMCP Submits Comments on Medicaid Drug Rebate Program Proposed Rule; House of Representatives Holds COVID-19 Vaccine and Coronavirus Response Hearings.
CMS Issues Proposed Rule Updating the Medicaid Drug Rebate Program; SAMHSA Publishes Final Rule Amending Substance Use Disorder Treatment Records Privacy; AMCP Joins Pharmacy Stakeholder Letter on Vaccine Administration; AMCP Signs Joint Comment Letter on Pharmacy Telehealth in Medicare.
AMCP Joins Pharmaceutical Supply Chain Stakeholders to Support Access to Medications; AMCP Comments on COVID-19 Changes to Medicare Program; FDA Issues RFI on Improving the Orange Book; CMS Issues Final Medicare Part C and Part D Policy, Technical Rule
